About Us

• Pharmacogenomics - toward new medicines in the post-genomic era
• The Publishing team
• The Editorial Advisory Board
• Background
• Audience
• Content
• Article types
• Features
• Additional Information

 Pharmacogenomics - toward new medicines in the post-genomic era

Pharmacogenomics is the definitive review journal for the post-genomic era, bringing you news, views and opinions in personalized medicine and genome research, both in print and on the web. Key objectives are to provide the community with an essential guide to the rapidly developing resources and technology in pharmacogenomics, deliver the latest news on exciting developments in the field and outline corporate capabilities and research activities.

Pharmacogenomics is the leading source of commentary and analysis, bringing you highest quality expert analysis from corporate and academic opinion leaders in the field. Articles are subject to rigorous peer review and benefit from an up-to-date, web-friendly format.

"Pharmacogenomics…has achieved a good balance between scientific accuracy and detail on one hand and readability on the other…and is exactly what is needed to promote the new developments in pharmacogenetics and pharmacogenomics"
Jurgen Brockmoller (Humbolt University of Berlin)

back to top...

 THE PUBLISHING TEAM

Pharmacogenomics is supported by a dedicated editorial team with extensive experience within pharmaceutical research and the publication of top-quality review journals. The Editor, Nadine Lemmens, studied Human Genetics at Leeds University, and her specialist interests include the ethical issues surrounding genetics. Nadine gained an international degree after a year's work experience in The Netherlands. Previously, she has been involved in the editorial development of publications such as Expert Opinion on Investigational Drugs.

The Editorial Director David Hughes received his MSc in the Applied Biology Department of the University of Wales in Cardiff and a PhD in pharmaceutical science from the University of Brighton School of Pharmacy. David founded Drug Discovery Today in 1996 and subsequently was responsible for the development of the Trends and Current Opinion review publishing programs of Elsevier Science. He is fascinated by the interface between the science and the business of biotechnology and maintains links to this community through his advisory role in events organized by companies such as IBC and Phacilitate.

Abi Akinwunmi is the latest member to join the team, after completing a degree in Biochemistry and Genetics at the University of Nottingham, and more recently a MSc in Bioinformatics at Imperial College London. She specialises in bioinfomatics resources for protein modeling and sequence analysis. She has a keen interest in the application of molecular technology in drug discovery.


back to top...

 THE EDITORIAL ADVISORY BOARD

Altshuler D  Whitehead Institute, USA
David M Altshuler MD, PhD is a human geneticist and clinical endocrinologist, whose research uses tools and information from the human genome project to investigate the genetic causes of common diseases. He is an Assistant Professor of Genetics and of Medicine at Harvard Medical School, and a member of the Department of Molecular Biology and Diabetes Unit at Massachusetts General Hospital. He is also Director of the Program in Medical and Population Genetics at the Whitehead Institute/MIT Center for Genome Research. A graduate of MIT and the MD/PhD program at Harvard Medical School, Dr. Altshuler completed clinical training in Internal Medicine and Endocrinolgy at MGH, and research training in the laboratories of Richard Mulligan, Connie Cepko, and Eric Lander. Currently, Dr. Altshuler focuses on genetic and genomic methods to dissect the genetic basis of common, polygenic diseases. Specific projects include the construction of a genome-wide map of common human sequence variation (as part of The SNP Consortium), studies of human population history, and genetic association studies of type II diabetes and hormone-responsive cancers. He is a member of Advisory Boards at multiple organizations, including The Marshfield Clinic, Genomics Collaborative, and Merck Research Laboratories.

Bailey D  Purely Proteins, UK
Dr David Bailey has held senior managerial positions at Smith Kline & French (Philadelphia, PA), Pfizer Central Research (Sandwich, UK) and Incyte Pharmaceuticals (Palo Alto, CA and Cambridge, UK). In 1999, David founded De Novo Pharmaceuticals with Dr Philip Dean of the University of Cambridge, becoming CEO. David left De Novo in June 2002 to become CEO of Purely Proteins.

Campbell DA  Etiologics, UK
Dr David Campbell joined Etiologics Ltd in January 2003 as Chief Scientific Officer. Prior to this Dr Campbell was Director and Head of Molecular Genetics at GlaxoSmithKline, UK having joined SmithKline Beecham from a post at the University of Leeds. An undergraduate of Strathclyde University, Dr Campbell was awarded his PhD from Glasgow University in 1995. Dr Campbell has published extensively in the field of human genetics and in recent years on the topic of pharmacogenetics.

Hákonarson H  Decode Genetics, Iceland
Dr. Hakonarson recieved his M.D. from the University of Iceland, School of Medicine, in 1986. He completed his subspeciality training in pulmonary medicine at the Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, where he became an Assistant Professor of Pediatrics. Hakon has received numerous awards from the University of Connecticut and University of Pennsylvania, and he is a Principal Investigator on a four year research grant from the National Institute of Health/National Heart Lung and Blood Institute. Dr. Hakonarson has major teaching and clinical responsibilities at the University of Pennsylvania and University of Iceland, and he has lectured extensively and presented scientific work at multiple international conferences. He is also a member of several scientific boards. Dr. Hakonarson has publised extensively in highly qualified peer reviewed scientific journals, and he has written several book chapters and reviews. Dr. Hakonarson defended his Ph.D. thesis at the University of Iceland on April 22nd 2002. Dr. Hakonarson currently heads the Respiratory and Pharmacogenomics Research Programs at deCODE Genetics Inc. In 2001 Dr. Hakonarson became chief scientific officer at Encode.

Hardiman G  California Univ., USA
Gary Hardiman, obtained his Ph.D in microbiology from the National University of Ireland (Galway) in 1993.  He completed postdoctoral research fellowships at DNAX Research Institute, Palo Alto, CA. In 1998 he joined Nemapharm, Cambridge MA as a Senior Scientist where he participated in the creation of 'NemaKnockouts': the high-throughput isolation of deletion mutants of C. elegans by direct PCR screening of chemically mutagenized nematode populations. Dr Hardiman relocated in late 1998 to Axys Pharmaceuticals (La Jolla) 'Sequana' where he was involved in the application of expression analysis to gene discovery in oncology and nematode functional genomics. In February 2000, Dr. Hardiman joined UCSD as the Director of The Biomedical Genomics Microarray (BIOGEM) Facility.  BIOGEM (http://biogem.ucsd.edu/) was established at the University of California San Diego to meet the needs of multiple labs interested in microarray technology.  The facility is a joint operation between the School of Medicine and the Division of Biology.  Dr. Hardiman is an instructor in the UCSD Extension Department of Bioscience where he teaches and advises on new courses offered in the areas of genomics, automation and bio-informatics.

Harris T  Structural GenomiX, USA
Dr Harris is currently the President and CEO of Structural GenomiX in San Diego. Through his career, Dr Harris has held a number of senior executive positions including Senior Vice President for Research and Development at Sequana Therapeutics (now Axys Pharmaceuticals), Director of Biotechnology at Glaxo Group Research in the UK and Head of Molecular Biology at Celltech Ltd. Dr Harris holds a PhD and MSc in Virology and a BSc in Biochemistry from the University of Birmingham in the UK.

Hein DW  Louisville Univ., USA
David W. Hein is the Peter K. Knoefel Endowed Chair in Pharmacology, Professor and Chairman of the Department of Pharmacology & Toxicology and Director of the Cancer Prevention & Control Program of the James Graham Brown Cancer Center at the University of Louisville. Dr. Hein received his BS degree in Chemistry from the University of Wisconsin-Eau Claire and his PhD in Pharmacology from the University of Michigan. He served previously as Chairman of the Departments of Pharmacology and Toxicology at The Morehouse School of Medicine and at the University of North Dakota. He was appointed Chester Fritz Distinguished Professor at the University of North Dakota and Distinguished University Scholar at the University of Louisville. His research focuses on the pharmacogenetics of drug metabolism, functional genomics, and genetic susceptibility to cancer from environmental carcinogens. He has authored over 125 journal articles / book chapters, and over 280 abstracts / communications. He has reviewed manuscripts for over 40 scientific journals.  Further information is available at: http://www.louisville.edu/~dwhein01.

Jackson R  Cyclacel Ltd, UK
Dr Robert Jackson, 59, joined Cyclacel Ltd in January 2001. Previously Research and Development Director and a member of the Board of Directors at Celltech Group plc, Europe's largest biotechnology company; Executive Director, Research and Development and Chief Operating Officer and a member of the Board of Directors at Chiroscience Group plc, which was acquired by Celltech in 1999. Prior to these appointments, he was Vice President, Research and Development at Agouron Pharmaceuticals, Inc., and headed cancer research at Du Pont Pharmaceuticals and Warner-Lambert Company. During his distinguished career he has been instrumental in the discovery and development of several marketed drugs used to treat cancer and other serious diseases.

Judson R  Genaissance, USA
Dr Judson is Senior Vice President of Informatics at Genaissance Pharmaceuticals where he manages the genetics, bioinformatics, software development, and algorithm development departments. His responsibilities include leading the development of the company's DecoGen™ System for analyzing genetic variation in clinical trials. Dr. Judson joined Genaissance in February 1999 as Associate Director of Informatics. From January 1997 to January 1999, Dr. Judson worked for CuraGen Corporation where he managed the development of software for protein-protein interactions and DNA sequence analysis. Previously, he spent seven years at Sandia National Laboratories leading projects in several areas including computational drug design, protein modeling and sequence analysis. Dr. Judson holds a Ph.D. and M.A. in Chemistry from Princeton University and a B.A. in Chemistry and Physics from Rice University.

Ladner RC  Dyax Corp., USA
Robert Charles Ladner, Ph.D. joined Dyax as Senior Vice President and Chief Scientific Officer in August 1995. He was a co-founder of Protein Engineering Corporation where he served as Senior Vice President and Scientific Director from 1987 until its merger with Dyax. Previously, Dr. Ladner served as Senior Scientist of Genex Corp., where he was an inventor of single chain antibodies.

Lennard MS Sheffield Univ., UK
Dr. M.S. Lennard is Reader in Pharmacology and Therapeutics, University of Sheffield. He is an Editor of the British Journal of Clinical Pharmacology and a former Secretary of the UK Drug Metabolism Group. His major research interest are in basic and clinical aspects of  drug metabolism, particularly cytochrome P450. He has been active in pharmacogenetics research for over 25 years.

Lennon G  Endogeny Bio, USA
Gregory G Lennon is the CEO and President of Endogeny Bio. Dr. Lennon was formerly the CSO and Senior VP for Research and Development at Gene Logic. He oversaw the scientific development of Gene Logic from an early stage to 3 years post IPO. Since Gene Logic, Dr. Lennon has been a consultant to several biotech companies and has served in interim executive management positions through his affiliations with various life science venture capital firms, such as Oxford Bioscience Partners. He is also the Chairman of the Scientific Advisory Board for Aptus Pharmaceuticals, and on the SAB of Psychiatric Genomics. Dr. Lennon has over 75 publications in the life sciences with a special emphasis on genomics. In the academic setting, he is best known as the founder of the I.M.A.G.E Consortium, the world’s largest public collection of gene clones. Clones from this collection form the basis of the vast majority of gene sequences in public sequence databases such as GenBank. Dr. Lennon received his Ph.D. in Genetics from the University of Pennsylvania.

Lindpaintner K  Hoffmann-La Roche, Switzerland
A native of Innsbruck, Austria, Klaus Lindpaintner graduated from the University of Innsbruck Medical School with a degree in Medicine and from Harvard University with a degree in Pub-lic Health. He pursued postgraduate training and specialization in Internal Medicine, Cardiol-ogy, and Genetics in the United States and Germany and holds board certifications these specialties. He practiced cardiology and pursued research in the area of cardiovascular dis-ease and  molecular genetics and genetic epidemiology, most recently as an Associate Pro-fessor of Medicine at Harvard Medical School in Boston, Massachusetts. He joined Roche Basel in 1997 as Head of Preclinical Research in Cardiovascular Diseases. Since 1998, he has been VP of Research and Director of Roche Genetics, coordinating the company’s ef-forts and activities in genetics, genomics, and proteomics. He has co-authored more than 100 original scientific papers, holds adjunct and honorary professorships at Harvard Univer-sity in Boston and University of London, and serves on the editorial board of several scien-tific journals. Klaus Lindpaintner lives near Basel, Switzerland; he is married to an internist, and has two daughters.

Liu L  Cambria Biosciences, USA
Leo Liu is the President and Chief Scientific Officer of Cambria Biosciences, a private biotechnology company that is focused on discovering new drug leads from sensitive phenotype-based screening methods.  Dr. Liu was most recently a Director of Scientific Strategy at Axys Pharmaceuticals.  A former faculty member at Harvard Medical School and Beth Israel Hospital, his expertise includes comparative genomics, emerging infectious diseases, and antiparasitic drugs.   Dr. Liu obtained his MD from Stanford University and postdoctoral training at Harvard Medical School and Imperial College, London.  He serves as an Overseer of the Boston Museum of Science and on the Corporation of the Jackson Laboratories.

McLeod HL  Washington Univ., USA
Dr Howard McLeod received his Bachelors of Science in Pharmacy from the University of Washington in Seattle and a PharmD degree from the Philadelphia College of Pharmacy and Science. He completed research fellowship training in cancer pharmacology at St Jude Children's Research Hospital, Memphis and the University of Glasgow, Scotland, before staying to direct the Clinical Pharmacology program at the Beatson Cancer Center in Glasgow.  He then moved to the University of Aberdeen, Scotland as Director of Laboratory Research for the Oncology Unit and returned to the USA in July 2000, as an Associate Professor of Medicine at Washington University.  Dr McLeod also holds appointments in the Departments of Molecular Biology & Pharmacology and Genetics at Washington University and is Director of the Siteman Cancer Center Pharmacology Core.  Dr McLeod is also the Principal Investigator for the CREATE Pharmacogenetics Research Network, a member of the NIH funded Pharmacogenetics Research Network.  Howard has published over 130 peer reviewed papers on cancer therapeutics, pharmacogenomics, or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine.

Murphy M  Gentris Corp., USA
Mr. Michael Murphy, M.Sc., CEO of Gentris Corporation, is recognized as one of the pioneers of the pharmacogenomics industry, having more than 19 years of scientific and business experience in the field of pharmacogenomics.  In 1997, he co-founded Intek Labs (now DNA Sciences Labs), the first international pharmacogenomic services company.  More recently he has held senior management positions with PPGx and Clingenix, Inc.  Mr. Murphy has been a key player in furthering the advancement of the pharmacogenomics industry by helping pharmaceutical companies implement clinical testing initiatives to improve the drug development process.  Mr. Murphy holds a Master of Science degree in Biology from San Diego State University, with an emphasis on molecular biology and genetics.  In addition, Mr. Murphy is a frequent lecturer and publisher on pharmacogenomics and was recently asked by the publishers of Pharmacogenomics and Drug Discovery World to author review articles on the current position of the industry.  Mr. Murphy’s current company, Gentris Corporation, is engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomic products and services. The company provides global pharmaceutical research organizations with turnkey pharmacogenomic solutions to improve the efficiency and predictability of drug development. 

Palfreyman M  NOVACE Corporation, USA
Dr. Palfreyman has over 25 years experience in the pharmaceutical and biotechnology industry having held a number of progressively more senior executive positions. Dr. Palfreyman obtained his Ph.D. and D.Sc. from the University of Nottingham in Neuroscience and Rational Drug Design, respectively. He started his career at Beecham Pharmaceuticals and built successful CNS and cardiovascular research groups. In 1975 he moved to the Merrell Research Institute, Strasbourg to lead a neuroscience group focusing on rational drug design and in 1985 was promoted to Director of Pharmacology and Head of CNS Research at the Merrell Dow Research Institute, Cincinnati where he eventually became Vice President of Research, North America. In 1994 he joined the start-up biotechnology company, Scriptgen as VP R&D where he developed a platform of cutting edged genomics based technologies to aid drug discovery in infectious diseases. As a founder of Psychiatric Genomics, he became President in March, 2000 and CSO in July, 2001. Dr. Palfreyman is currently a Principal at NOVACE Corp. and has 35 issued patents, over 100 publications and is the editor of two scientific books.

Poste G  Health Tech. Networks, USA
Dr. Poste is Chief Executive of Health Technology Networks, a consulting group specializing in the application of genomics technologies and computing in healthcare.  From 1992 to 1999 he was Chief Science and Technology Officer and President, Research and Development of SmithKline Beecham (SB).  During his tenure at SB he was associated with the successful registration of 29 drug, vaccine and diagnostic products.  Dr. Poste is Chairman of diaDexus and Structural GenomiX in California and serves on the Board of Directors of Maxygen, Illumina and Orchid Biosciences.  He is also advisor to several venture capital funds.  He is a fellow of Pembroke College Cambridge and Distinguished Fellow at the Hoover Institution and Stanford University.  He is a member of the Defense Science Board of the U.S. Department of Defense and in this capacity he Chairs the Task Force on Bioterrorism.  He is also a member of the National Academy of Sciences Working Group on Defense Against Bioweapons. Dr. Poste is a Board Certified Pathologist, a Fellow of the Royal Society, the National Academy of Great Britain and a Fellow of the Academy of Medical Sciences.  He has published over 350 scientific papers, co-edited 15 books on cancer, biotechnology and infectious diseases and serves on the Editorial Board of multiple technical journals. He is invited routinely to be the keynote speaker at a wide variety of academic, corporate, investment and government meetings to discuss the impact of biotechnology and genetics on healthcare and the challenges posed by bioterrorism. Dr. Poste is married with three children.  His personal interests are in military history, photography, automobile racing and exploring the wilderness zones of the American West.

Ruano G  Genaissance, USA
Dr. Ruaño recently assumed the duties of Vice Chairman and Chief Scientific Officer. Previously, he was CEO since the Company's inception in 1997 and a founder of Genaissance Pharmaceuticals, Inc. Dr. Ruaño is a pioneer in several molecular technologies for profiling genome diversity, stemming from population and evolutionary genetics. He is the inventor of the CAS System (U.S. patent 5,427,911) for the rapid determination of sequence variation, which is now used for HIV diagnosis and AIDS clinical management. Dr. Ruaño has consulted with the Forensic Laboratory of the Connecticut Department of Public Safety to establish the DNA Analysis Unit and with Connecticut Innovations, Inc. to evaluate technologies of portfolio companies. He is considered one of the industry's leaders in the impact of gene variation on clinical medicine and drug development.

Sim E  Oxford Univ., UK
Professor Edith Sim graduated from Edinburgh University in Biochemistry and came to Oxford in 1973. She gained her DPhil in 1976. After two years funded by a Royal Society European Exchange Fellowship in Genoble studying membrane proteins, she returned to Oxford as a Demonstrator in the Biochemistry Department to work on innate immunity. She was appointed to a Wellcome Trust Senior Lecturer in the Pharmacology Department in 1983 to study individual susceptibility to immunotoxicity. Professor Sim’s interests in susceptibility to toxicity have extended to understanding the molecular basis of different responses of individuals to environmental components which contribute to development of disease. Appointed to a College Fellowship in Biochemistry in 1992, she takes up a University Lectureship in this Department in 1999. Professor Sim is also the Director of Graduate Studies at Oxford University.

Richard J Warburg  Foley & Lardner, USA
Richard J Warburg is a partner in the Intellectual Property Department of Foley & Lardner's San Diego office. Dr Warburg specializes in the biotechnology, pharmaceutical and chemical industries. His areas of client counsel include intellectual property litigation, strategic counseling and patent prosecution, and he has been lead counsel on a variety of patent and trade secret lawsuits. Over the past 18 years, Dr Warburg's practice has involved him in a variety of technical fields, including genetic engineering, immunology, animal cloning, biomedical devices and diagnostics. He also has secured patent protection for innovations worldwide. Dr Warburg is registered to practice before the US Patent and Trademark office. His practice admissions also include the states of California and Massachusetts, and the US Courts of Appeals for the Ninth and Federal Circuits. Dr Warburg is a graduate of Birmingham University, England, where he received his Bachelor of Science degree in 1978 and his PhD in molecular biology in 1981. His law degree was conferred, magna cum laude, by Suffolk University in 1990 as Valedictorian.

Winkelmann BR  Heidelberg Univ., DL
Dr. Winkelmann has been trained in medical information science and in internal medicine at the Universities of California at San Francisco, Frankfurt and Heidelberg  and worked as a cardiologist in the University of Frankfurt until 1994. He took over a job as clinical project manager in the pharmaceutical industry from 1994-1997 and recently joined the Department of Internal Medicine VI as  the head of the Cooperation Unit Pharmacogenomics / Applied Genomics Heidelberg, which was founded in 2001 by the Department of Internal Medicine VI (Clinical Pharmacology and Phar-macoepidemiology) and the Coordination Centre for Clinical Trials at the University of Heidelberg. His main interests are sophisticated pheno-typing procedures for patient characterization and the conduct of multicenter clinical trials according to international standards with state-of-the-art data management. He currently applies new genomic tools in order to achieve progress in personalized medicine using collaborating networks of general practitioners for patient enrolment.

Wolf CR  Dundee Univ., UK
Professor C R Wolf is the Director of the University of Dundee Biomedical Research Centre and the Honorary Director of the Cancer Research UK Molecular Pharmacology Unit, Dundee, United Kingdom. His major research interests revolve around understanding the factors which determine the sensitivity or resistance of cells to chemical agents.  Studies have involved detailed analysis of the molecular biology and genetics of drug metabolising enzymes including the cytochrome P450 and glutathione S-transferase systems as well as other proteins, such as drug transporters, involved in drug absorption and distribution.  This work has also involved studies into genetic polymorphisms in genes which may determine drug response, particularly in the area of pharmacogenetics, e.g. the discovery of the major gene-activating changes involved in the cytochrome P450 CYP2D6 (debrisoquine hydroxylase) polymorphism. Prof. Wolf is a member of many national and international committees dealing with different aspects of pharmacogenetics and pharmacogenomics. Current interests include the development of new pharmacogenomic and pharmacogenetic strategies applied to the more rapid and more predictive development of new drugs.

Xanthopoulos K  Anadys Pharm., Inc., USA
Dr. Xanthopoulos is the President and CEO of Anadys Pharmaceuticals, Inc.  Previously, he was a VP of Genomics & Molecular Biology at Aurora Biosciences Corp., where he developed and commercialized Aurora’s genomics business.  Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at NIH and he is currently an adjunct Associate Professor at the University of Utah Medical School, Salt Lake City.  Previously, he held an Associate Professorship at the Karolinska Nobel Medical Institute, Stockholm, Sweden.  Dr. Xanthopoulos graduated from the Aristotle University of Thessaloniki, Greece (1980), and received both his M.Sc. in Microbiology (1982) and Ph.D. in Molecular Biology (1986) from the University of Stockholm, Sweden.  He is an Onassis Scholar, a Greek Government Distinguished Fellow, the recipient of Swedish National Sciences Foundation awards and was a National Institutes of Health Fellow at the Rockefeller University, New York, 1987-1990.  He is also the author of more than 60 peer review publications and a member of several editorial boards.

Xie H-G Vanderbilt Univ., USA
Dr Hong-Guang Xie is currently a Research Instructor in Clinical Pharmacology at Vanderbilt University School of Medicine. He holds his Bachelor’s, Master’s, and Doctoral degrees in Medicine from Central South University Xiang Ya School of Medicine (formerly Hunan Medical University, HMU) in China, where he subsequently became an Associate Professor of Pharmacology, the founding Associate Director of and also the co-founder of the Pharmacogenetics Research Institute at the HMU. In 1997, Dr Xie went to the USA and did his postdoctoral research in the Division of Clinical Pharmacology at Vanderbilt University Medical Center as the recipient of a Merck Sharp and Dohme International Fellowship in Clinical Pharmacology, and joined the faculty of Vanderbilt School of Medicine after completing his research fellowship training. Dr Xie has a broad understanding and interest in biomedical sciences, and has been active in the field of research relating to clinical pharmacology and therapeutics for many years. His work has ranged broadly from the metabolism of and response to clinical drugs to their molecular pharmacogenetics and pharmacogenomics, with a special emphasis on the molecular genetic basis of ethnic variability in drug disposition and response. Dr Xie has authored many peer-reviewed original research papers and review articles in the leading journals of life science including the New England Journal of Medicine, and Annual Review of Pharmacology and Toxicology, and published several book chapters. In addition, Dr Xie served or is serving as a reviewer of multiple professional journals published in the UK and US, such as Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology, Pharmacogenetics, and Expert Opinion on Drug Safety.

Zhao H  Yale Univ., USA

Bader JS  CuraGen, USA
Benjamin M  Rosetta, USA
Bennett CF  ISIS Pharm., USA
Boehm B  Mediz. Universitatsklinik, DL
Cohen D  Novartis, USA
Clayton CL  GlaxoSmithKline, UK
Dykes C  OpGen Inc., USA
Freeman T  Wellcome Trust, UK
Gurwitz D  Tel-Aviv Univ., Israel
Ishikawa I  Tokyo Institute of Technology, Japan
Jung V  Cereon Genomics USA
Lipshutz RJ  Affymetrix, USA
März W  Albert Ludwigs Univ., DL
Moyses C  Oxford Glycosciences, UK
Osborne M  Millennium Pharm., USA
Plasterk R  Hubrecht Lab., ND
Roberds SL  Pharmacia Corp., USA
Shen E   MDS Pharma Services, USA
Silber BM  Pfizer, USA
Spence P  Monsanto, USA
Wang D  Bristol-Myers Squibb, USA

back to top...

 BACKGROUND

Pharmacogenomics seeks to apply technologies, methods and discoveries from the field of genomics to improve the efficacy and safety of therapeutics. A search of published literature reveals practically no incidence of the term pharmacogenomics prior to 1997, yet this field now promises to revolutionize the practice of medicine. By understanding how an individual's genetic inheritance affects the body's variable response to drugs, pharmaceutical manufacturers will eventually be able to produce personalized drugs. Tailor-made medicines could potentially eliminate harmful drug interactions while enhancing drug efficacy and safety, and improving treatment outcomes. Major initiatives in genomics over the last decade are now impacting on drug discovery and creating remarkable opportunities. Pharmacogenomics was established in 2000 with aim of becoming the most comprehensive single source to address the development of this rapidly expanding field.

back to top...

 AUDIENCE

The audience for Pharmacogenomics consists of clinicians, R&D professionals and decision-makers in the pharmaceutical and biotech industries, as well as academic researchers and technology specialists within associated institutions.

back to top...

 CONTENT

Pharmacogenomics is distinguished from other publications by its critical mass of expertly drafted review articles, structured to reflect the author's own expertise and vision. At the end of each paper you will find Highlights, an executive summary of the authors' main points, useful for time-constrained readers requiring a rapidly accessible overview. In the Outlook section, authors are challenged to include a speculative viewpoint on how the field will evolve over the next 5-10 years.

 ARTICLE TYPES

Article formats will reflect the author's area of expertise and the particular emphasis of each paper. Sample papers and guidelines are available for each type of article. Please contact the Editor if you are interested in contributing to the journal.

Editorials
Each issue is lead by an editorial paper focussing on a topical area of pharmacogenomics.
Sample Editorial

Reviews
Reviews are commissioned from genomics experts in academia and industry. Articles concentrate on the most recent developments in the pharmacogenomics field and aim to summarize current therapeutic practice, highlighting recent significant advances in research, ongoing challenges and unmet needs.
Sample Review Article

Primary Articles
These are reports whose conclusions represent a substantial advance in the understanding of an important problem. They comprise of an Introduction, Materials and Methods (including ethical and statistical information), Results and Discussion (including a conclusion drawn from the research presented).
Author Guidelines for Primary Articles

Perspectives
These should be speculative and very forward looking, even visionary. They also offer the author the opportunity to present criticism or address controversy. Authors of perspectives are encouraged to be highly opinionated. The intention is very much that perspectives should represent a personal perspective.
Sample Perspective

Technology Reports
These articles focus on a specific technology or approach, profiling innovative drug discovery-associated genome-based technologies which promise to unlock new opportunities for drug discovery.
Sample Technology Report

Company Profiles
Company Profiles in Pharmacogenomics allow pharmaceutical and biotechnology companies to describe the work currently being carried out within their particular organisation. These reports are intended to provide an insight into the history and strategy of a company and profile its corporate capabilities, advanced technologies and future potential.
Sample Company Profile

Conference Reports
Recent pharmacogenomics-related meetings are reviewed in detail in the Conference Scene.
Sample Conference Report

 FEATURES

The Bulletin Board brings you the latest news and views and the Calendar features upcoming pharmacogenomics-related conferences.

back to top...

 Additional Information

EDITORIAL POLICY
Articles published in Pharmacogenomics are commissioned by the Editor in collaboration with the Editorial Board. Authors who wish to contribute should contact the Editor in the first instance.

CITATIONS
Pharmacogenomics is indexed by Medline, Science Citation Index Expanded, ISI Alerting Services, Biotechnology Citation Index and Chemical Abstracts.

COPYRIGHT
Conditions of sale: Pharmacogenomics may be circulated only to those members of staff who are employed at the site at which the subscription is taken out. Readers are reminded that, under internationally agreed copyright legislation, photocopying of copyright materials is prohibited other than on a limited basis for personal use. This means that making copies of any article published in Pharmacogenomics is a breach of the law and can be prosecuted.

DISCLAIMER
Whilst every effort is made by the Publisher and Editorial Board to ensure that no inaccurate or misleading data, opinions or statements appear in this journal, they wish to make it clear that the data and opinions appearing herein are the responsibility of the contributor concerned. Accordingly, the Publisher, Editorial Board and their respective employees, officers and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinions or statements.

ISSN NUMBER
1462-2416

back to top...